Cholesterol screening and management in children and young adults should start early - NO!

Clinical Cardiology

Volumn 35, Issue 11, 2012, Pages 665-668

  Schroeder, Alan R ^a   Redberg, Rita F ^b  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CLOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TORCETRAPIB;

CARDIOVASCULAR RISK; CHILD HEALTH CARE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG LABELING; DRUG SAFETY; EARLY INTERVENTION; EATING DISORDER; FAMILIAL HYPERCHOLESTEROLEMIA; GROUPS BY AGE; HUMAN; LIPID ANALYSIS; MYOPATHY; NEEDLESTICK INJURY; PRACTICE GUIDELINE; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SCREENING TEST; SIDE EFFECT;

ADOLESCENT; AGE FACTORS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; HUMANS; HYPERCHOLESTEROLEMIA; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; YOUNG ADULT;

EID: 84869390786     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22075     Document Type: Review

References (42)

1. Berwick DM, Hackbarth AD., Eliminating waste in US health care. JAMA. 2012; 307: 1513-1516.
2. Welch HG, Albertsen PC., Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009; 101: 1325-1329.
3. Hulley S, Grady D., Postmenopausal hormone treatment. JAMA. 2009; 301: 2493-2495.
4. US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: full report. 2011. http://www.nhlbi.nih.gov/guidelines/cvd-ped/ index.htm. Accessed August 18, 2012.
5. Psaty BM, Rivara FP., Universal screening and drug treatment of dyslipidemia in children and adolescents. JAMA. 2012; 307: 257-258.
6. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992; 89: 495-501.
7. Newman TB, Pletcher MJ, Hulley SB., Overly aggressive new guidelines for lipid screening in children: evidence of a broken process. Pediatrics. 2012; 130: 349-352.
8. Kit BK, Carroll MD, Lacher DA, et al. Trends in serum lipids among US youths aged 6 to 19 years, 1988-2010. JAMA. 2012; 308: 591-600.
9. de Ferranti SD., Declining cholesterol levels in US youths: a reason for optimism. JAMA. 2012; 308: 621-622.
10. Blumenthal RS, Redberg, R., Should healthy people take cholesterol drugs to prevent heart disease? Wall Street Journal. January 23, 2012. http://online.wsj.com/article/SB10001424052970203471004577145053566185694.html. Accessed August 24, 2012.
11. Redberg RF, Katz MH., Healthy men should not take statins. JAMA. 2012; 307: 1491-1492.
12. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010; 170: 1024-1031.
13. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011;(1): CD004816.
14. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380: 581-590.
15. McMurtry CM, Noel M, Chambers CT, et al. Children's fear during procedural pain: preliminary investigation of the Children's Fear Scale. Health Psychol. 2011; 30: 780-788.
16. Lannon CM, Earp J., Parents' behavior and attitudes toward screening children for high serum cholesterol levels. Pediatrics. 1992; 89 (6 pt 2): 1159-1163.
17. Braamskamp MJ, Wijburg FA, Wiegman A., Drug therapy of hypercholesterolaemia in children and adolescents. Drugs. 2012; 72: 759-772.
18. US Department of Health and Human Services;US Food and Drug Administration. FDA announces safety changes in labeling for some cholesterol-lowering drugs. February 28, 2012. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm293623.htm. Accessed August 24, 2012.
19. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012; 172: 144-152.
20. Fernandez G, Spatz ES, Jablecki C, et al. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011; 78: 393-403.
21. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patientsâ€" the PRIMO study. Cardiovasc Drugs Ther. 2005; 19: 403-414. (Pubitemid 43228152)
22. Buettner C, Davis RB, Leveille SG, et al. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med. 2008; 23: 1182-1186.
23. Clauss SB, Holmes KW, Hopkins P, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics. 2005; 116: 682-688. (Pubitemid 44336686)
24. de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002; 106: 2231-2237. (Pubitemid 35222218)
25. Knipscheer HC, Boelen CC, Kastelein JJ, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res. 1996; 39: 867-871. (Pubitemid 26130029)
26. Lambert M, Lupien PJ, Gagne C, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics. 1996; 97: 619-628. (Pubitemid 26138089)
27. McCrindle BW, Ose L, Marais AD., Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003; 143: 74-80. (Pubitemid 36928572)
28. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007; 116: 664-668. (Pubitemid 47356351)
29. Stein EA, Illingworth DR, Kwiterovich PO Jr, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 1999; 281: 137-144. (Pubitemid 29045345)
30. van der Graaf A, Nierman MC, Firth JC, et al. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia. Acta Paediatr. 2006; 95: 1461-1466. (Pubitemid 44643563)
31. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004; 292: 331-337. (Pubitemid 38944256)
32. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003; 326: 1167-1170. (Pubitemid 36649048)
33. Newman TB, Garber AM., Cholesterol screening in children and adolescents. Pediatrics. 2000; 105 (3 pt 1): 637-638. (Pubitemid 30129683)
34. Rosen DS., Identification and management of eating disorders in children and adolescents. Pediatrics. 2010; 126: 1240-1253.
35. Shapiro S, Newcomb M, Loeb TB., Fear of fat, disregulated-restrained eating, and body-esteem: prevalence and gender differences among eight- to ten-year-old children. J Clin Child Psychol. 1997; 26: 358-365.
36. McCrindle BW, Kwiterovich PO, McBride PE, et al. Guidelines for lipid screening in children and adolescents: bringing evidence to the debate. Pediatrics. 2012; 130: 353-356.
37. Haney EM, Huffman LH, Bougatsos C, et al. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics. 2007; 120: e189-e214. (Pubitemid 47036251)
38. Ritchie SK, Murphy EC, Ice C, et al. Universal versus targeted blood cholesterol screening among youth: The CARDIAC project. Pediatrics. 2010; 126: 260-265.
39. Gillman MW, Daniels SR., Is universal pediatric lipid screening justified? JAMA. 2012; 307: 259-260.
40. US Preventive Services, Task Force. Screening for lipid disorders in adults. June 2008. http://www.uspreventiveservicestaskforce.org/uspstf/uspschol. htm. Accessed September 21, 2012.
41. Moynihan R., Medicalization. A new deal on disease definition. BMJ. 2011; 342: d2548.
42. Schroeder AR, Harris SJ, Newman TB., Safely doing less: a missing component of the patient safety dialogue. Pediatrics. 2011; 128: e1596-e1597.